Skip to main navigation Skip to search Skip to main content

Initial genome sequencing and analysis of multiple myeloma

  • Michael A. Chapman
  • , Michael S. Lawrence
  • , Jonathan J. Keats
  • , Kristian Cibulskis
  • , Carrie Sougnez
  • , Anna C. Schinzel
  • , Christina L. Harview
  • , Jean Philippe Brunet
  • , Gregory J. Ahmann
  • , Mazhar Adli
  • , Kenneth C. Anderson
  • , Kristin G. Ardlie
  • , Daniel Auclair
  • , Angela Baker
  • , P. Leif Bergsagel
  • , Bradley E. Bernstein
  • , Yotam Drier
  • , Rafael Fonseca
  • , Stacey B. Gabriel
  • , Craig C. Hofmeister
  • Sundar Jagannath, Andrzej J. Jakubowiak, Amrita Krishnan, Joan Levy, Ted Liefeld, Sagar Lonial, Scott Mahan, Bunmi Mfuko, Stefano Monti, Louise M. Perkins, Robb Onofrio, Trevor J. Pugh, S. Vincent Rajkumar, Alex H. Ramos, David S. Siegel, Andrey Sivachenko, A. Keith Stewart, Suzanne Trudel, Ravi Vij, Douglas Voet, Wendy Winckler, Todd Zimmerman, John Carpten, Jeff Trent, William C. Hahn, Levi A. Garraway, Matthew Meyerson, Eric S. Lander, Gad Getz, Todd R. Golub
  • Broad Institute
  • Cambridge University Hospitals NHS Foundation Trust
  • Mayo Clinic Scottsdale, AZ
  • Multiple Myeloma Research Consortium
  • Dana-Farber Cancer Institute
  • Massachusetts General Hospital
  • Multiple Myeloma Research Foundation
  • Translational Genomics Research Institute
  • Harvard University
  • Howard Hughes Medical Institute
  • Weizmann Institute of Science
  • Ohio State University
  • Saint Vincent Catholic Medical Centers
  • University of Michigan, Ann Arbor
  • City of Hope National Med Center
  • Emory University
  • Mayo Clinic Rochester, MN
  • Princess Margaret Hospital
  • Washington University St. Louis
  • The University of Chicago
  • Massachusetts Institute of Technology

Research output: Contribution to journal › Article › peer-review

1305 Scopus citations

Abstract

Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly understood. Here we report the massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs. Several new and unexpected oncogenic mechanisms were suggested by the pattern of somatic mutation across the data set. These include the mutation of genes involved in protein translation (seen in nearly half of the patients), genes involved in histone methylation, and genes involved in blood coagulation. In addition, a broader than anticipated role of NF-Î °B signalling was indicated by mutations in 11 members of the NF-Î °B pathway. Of potential immediate clinical relevance, activating mutations of the kinase BRAF were observed in 4% of patients, suggesting the evaluation of BRAF inhibitors in multiple myeloma clinical trials. These results indicate that cancer genome sequencing of large collections of samples will yield new insights into cancer not anticipated by existing knowledge.

Original languageEnglish
Pages (from-to)467-472
Number of pages6
JournalNature
Volume471
Issue number7339
DOIs
StatePublished - 24 Mar 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Initial genome sequencing and analysis of multiple myeloma'. Together they form a unique fingerprint.

Cite this